Abstract
The last decade has been very important for the quantity of preclinical information obtained regarding chronic myeloproliferative neoplasms (MPNs) and the following will be dedicated to the translational implications of the new biological acquisitions. The overcoming of the mechanistic model of clonal evolution and the entry of chronic inflammation and dysimmunity into the new model are the elements on which to base a part of future therapeutic strategies. The innate immune system plays a major role in this context. Protagonists of the initiation and regulation of many pathological aspects, from cytokine storms to fibrosis, the NLRP3 and AIM2 inflammasomes guide and condition the natural history of the disease. For this reason, MPNs share many biological and clinical aspects with non-neoplastic diseases, such as autoimmune disorders. Finally, cardiovascular risk and disturbances in iron metabolism and myelopoiesis are also closely linked to the role of inflammasomes. Although targeted therapies are already being tested, an increase in knowledge on the subject is desirable and potentially translates into better care for patients with MPNs.
Highlights
Is a serine/threonine kinase involved in the regulation of innate immunity that is recruited by MyD88 following the activation of the toll-like receptor (TLR) and interleukin receptor, initiating a signaling cascade that induces cytokine and survival factor expression mediated by the transcription factor NF-KB
The biological complexity of myeloproliferative neoplasms (MPNs) is still far from being revealed, but new insights into the role of inflammasomes are allowing the development of new treatment strategies
Aware of the potential scarce applicability of this approach, as it is not yet universally accepted, it would be important for hematologists or oncologists to acquire a multidisciplinary competence for a broader and more correct interpretation of these diseases and their management
Summary
Valeria Di Battista 1,† , Maria Teresa Bochicchio 2,† , Giulio Giordano 3 , Mariasanta Napolitano 4,‡.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have